1
Country: USA | Funding: $316.6M
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
2
Country: USA | Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
3
Country: USA | Funding: $100M
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
4
Country: Japan | Funding: ¥8.3B
We challenge to integrate and develop nano and bio technologies. Our mission is to contribute to people's health and well-being with better process and quality.
We challenge to integrate and develop nano and bio technologies. Our mission is to contribute to people's health and well-being with better process and quality.
5
Country: USA | Funding: $13.5M
Zylö Therapeutics has an innovative sustained-release drug-delivery system that uses patented hydrogel-derived nanoparticles
Zylö Therapeutics has an innovative sustained-release drug-delivery system that uses patented hydrogel-derived nanoparticles
6
Country: USA | Funding: $2.4M
Nanomedical Diagnostics is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. Our ongoing mission is applying our cutting-edge capabilities to produce affordable diagnostic and monitoring platforms that deliver accurate, timely health information and improve patient outcomes and lives.
Nanomedical Diagnostics is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. Our ongoing mission is applying our cutting-edge capabilities to produce affordable diagnostic and monitoring platforms that deliver accurate, timely health information and improve patient outcomes and lives.
7
Country: Australia | Funding: $5.1M
iCeutica has developed the Encapsulated Organic Nanoparticles (EON™) Platform to produce consistent nano-sized drug particles.
iCeutica has developed the Encapsulated Organic Nanoparticles (EON™) Platform to produce consistent nano-sized drug particles.
8
Country: USA | Funding: $4.6M
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
9
Country: USA
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
10
Country: Germany
Bio-Gate is a company that employs unique silver technology to endow materials and products with antimicrobial properties. The focus of the product portfolio is medical technology products. Our different technologies are also used to refine cosmetics, consumer goods and industrial products. The company employs two techologies: MicroSilver and HyProtect.
Bio-Gate is a company that employs unique silver technology to endow materials and products with antimicrobial properties. The focus of the product portfolio is medical technology products. Our different technologies are also used to refine cosmetics, consumer goods and industrial products. The company employs two techologies: MicroSilver and HyProtect.
11
Country: India
Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid- Nanoengineering water soluble drugs with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid- Nanoengineering water soluble drugs with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
12
Country: USA
Illuminate Therapeutics is a spin-off of Pennsylvania State University developing an effective and targeted treatment for head and neck cancer that will cause minimal damage to surrounding healthy tissue. The potential treatment utilizes Illuminate's drug delivery and release platform based on light-activated nanoparticles (LADDR). It uses very focused laser to activate a light sensitive nanoparticle that delivers a nucleic acid that would target many different genes within the cancer cell. Such a precise methodology enables to use more potent chemicals to target the cancer cell.
Illuminate Therapeutics is a spin-off of Pennsylvania State University developing an effective and targeted treatment for head and neck cancer that will cause minimal damage to surrounding healthy tissue. The potential treatment utilizes Illuminate's drug delivery and release platform based on light-activated nanoparticles (LADDR). It uses very focused laser to activate a light sensitive nanoparticle that delivers a nucleic acid that would target many different genes within the cancer cell. Such a precise methodology enables to use more potent chemicals to target the cancer cell.
